Company intelligence / Profile preview

ImmunoScience, Inc.

Dublin-Pleasanton area*, California, United Statessanofi.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Contre Vir™, a recombinant live attenuated therapeutic vaccine targeting HIV/AIDS, has demonstrated high success rates in pre-clinical studies and pilot clinical trials. The company is preparing to initiate Phase I clinical trials internationally. A second program targets various cancers with a similar recombinant vaccine approach currently at proof-of-concept/animal study stage.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant live attenuated therapeutic vaccinesDiagnostic devices (e.g., saliva-based rapid diagnostic test for HIV)
Industry: Biotech

Drug pipeline

2 assets

iluzanebart

Phase 1

Indications: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on ImmunoScience, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoScience, Inc..

Explore the full profile